Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Accessibility StatementSkip Navigation -- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 -- -- Dosing of patients in Part A open-label extension (OLE) ongoing -- -- Cash and cash equivalents of $49.0 million as of September 30, 2025 expected to provide financial runway into 2027 -- Financial Results Completed enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial and inc ...